Short-term effect of sacubitril/valsartan on endothelial dysfunction and arterial stiffness in patients with chronic heart failure

• Main Authors: Velia Cassano (Author), Giuseppe Armentaro (Author), Marcello Magurno (Author), Vincenzo Aiello (Author), Francesco Borrello (Author), Sofia Miceli (Author), Raffaele Maio (Author), Maria Perticone (Author), Alberto M. Marra (Author), Antonio Cittadini (Author), Marta L. Hribal (Author), Francesco Andreozzi (Author), Giorgio Sesti (Author), Angela Sciacqua (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Heart failure (HF) is associated to endothelial dysfunction that promotes the increase of arterial stiffness thus augmenting myocardial damage. Sacubitril/Valsartan is used in the treatment of HF reduced ejection fraction (HFrEF) and has been proven effective in reducing cardiovascular disease (CVD)...